Athira Pharma Stock Price Prediction
| ATHA Stock | USD 0.64 0.02 3.03% |
Oversold Vs Overbought
46
Oversold | Overbought |
EPS Estimate Next Quarter (0.48) | Wall Street Target Price 0.55 | EPS Estimate Current Quarter (0.71) |
Using Athira Pharma hype-based prediction, you can estimate the value of Athira Pharma from the perspective of Athira Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Athira Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Athira because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Athira Pharma after-hype prediction price | USD 0.67 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Athira |
Athira Pharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Athira Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Athira Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Athira Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Athira Pharma Estimiated After-Hype Price Volatility
In the context of predicting Athira Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Athira Pharma's historical news coverage. Athira Pharma's after-hype downside and upside margins for the prediction period are 0.03 and 13.33, respectively. We have considered Athira Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Athira Pharma is extremely dangerous at this time. Analysis and calculation of next after-hype price of Athira Pharma is based on 3 months time horizon.
Athira Pharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Athira Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Athira Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Athira Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.09 | 12.66 | 0.01 | 0.33 | 7 Events / Month | 7 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.64 | 0.67 | 1.52 |
|
Athira Pharma Hype Timeline
Athira Pharma is presently traded for 0.64. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of -0.33. Athira is forecasted to increase in value after the next headline, with the price projected to jump to 0.67 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 1.52%, whereas the daily expected return is presently at -1.09%. The volatility of related hype on Athira Pharma is about 4167.9%, with the expected price after the next announcement by competition of 0.31. Net Loss for the year was (117.67 M) with profit before overhead, payroll, taxes, and interest of 0. Given the investment horizon of 90 days the next forecasted press release will be in about 7 days. Check out Athira Pharma Basic Forecasting Models to cross-verify your projections.Athira Pharma Related Hype Analysis
Having access to credible news sources related to Athira Pharma's direct competition is more important than ever and may enhance your ability to predict Athira Pharma's future price movements. Getting to know how Athira Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Athira Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CTMX | CytomX Therapeutics | (0.01) | 9 per month | 0.00 | (0.18) | 5.00 | (5.49) | 20.61 | |
| SPRO | Spero Therapeutics | 0.02 | 10 per month | 0.00 | (0.12) | 3.79 | (4.58) | 14.92 | |
| NLTX | Neoleukin Therapeutics | (0.14) | 1 per month | 0.00 | (0.08) | 4.05 | (3.53) | 27.84 | |
| TIL | Instil Bio | (1.77) | 9 per month | 6.84 | 0.12 | 20.63 | (10.89) | 105.83 | |
| NXTC | NextCure | 0.01 | 5 per month | 0.00 | (0.12) | 5.22 | (5.52) | 21.68 | |
| ASMB | Assembly Biosciences | (0.72) | 7 per month | 4.40 | (0) | 8.49 | (5.34) | 24.80 | |
| ACHL | Achilles Therapeutics PLC | (0.03) | 4 per month | 1.56 | 0.12 | 3.06 | (2.88) | 38.16 | |
| NUVB | Nuvation Bio | 0.21 | 8 per month | 4.53 | (0.01) | 9.48 | (8.36) | 21.30 |
Athira Pharma Additional Predictive Modules
Most predictive techniques to examine Athira price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Athira using various technical indicators. When you analyze Athira charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Athira Pharma Predictive Indicators
The successful prediction of Athira Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Athira Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Athira Pharma based on analysis of Athira Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Athira Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Athira Pharma's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 28.07 | 9.68 | 5.37 | 5.1 | Net Debt To EBITDA | 2.0 | 0.99 | 0.76 | 0.72 |
Story Coverage note for Athira Pharma
The number of cover stories for Athira Pharma depends on current market conditions and Athira Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Athira Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Athira Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Athira Pharma Short Properties
Athira Pharma's future price predictability will typically decrease when Athira Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Athira Pharma often depends not only on the future outlook of the potential Athira Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Athira Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 38 M | |
| Cash And Short Term Investments | 147.4 M |
Complementary Tools for Athira Stock analysis
When running Athira Pharma's price analysis, check to measure Athira Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Athira Pharma is operating at the current time. Most of Athira Pharma's value examination focuses on studying past and present price action to predict the probability of Athira Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Athira Pharma's price. Additionally, you may evaluate how the addition of Athira Pharma to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |